Joseph A. Barbarite
Compliance Officer presso PAR PHARMACEUTICAL COMPANIES, INC.
Profilo
Joseph A.
Barbarite is currently the Senior Vice President-Quality & Compliance at Endo Generics Holdings, Inc. He previously worked as the Director-Quality Assurance at Forest Laboratories, Inc. and as the EVP-Global Quality & Compliance at Endo International Plc from 2016 to 2022.
He also held the position of Senior Vice President- Global Quality & Compliance at Par Pharmaceutical, Inc. Mr. Barbarite completed his undergraduate degree at Fordham University.
Posizioni attive di Joseph A. Barbarite
| Società | Posizione | Inizio |
|---|---|---|
| PAR PHARMACEUTICAL COMPANIES, INC. | Compliance Officer | - |
Precedenti posizioni note di Joseph A. Barbarite
| Società | Posizione | Fine |
|---|---|---|
| ENDO INTERNATIONAL PLC | Compliance Officer | 01/06/2022 |
Par Pharmaceutical, Inc.
 Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Compliance Officer | - |
| FOREST LABORATORIES, INC. | Corporate Officer/Principal | - |
Formazione di Joseph A. Barbarite
| Fordham University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ENDO INTERNATIONAL PLC | Health Technology |
| Aziende private | 3 |
|---|---|
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY. | Health Technology |
Endo Generics Holdings, Inc.
 Endo Generics Holdings, Inc. Pharmaceuticals: GenericHealth Technology Endo Generics Holdings, Inc. develops, manufactures, and markets generic pharmaceutical products. It also offers dosage, branded, and generic sterile injectable products. The company was founded in 1978 and is headquartered in New York, NY. | Health Technology |
Par Pharmaceutical, Inc.
Par Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Par Pharmaceutical, Inc. manufactures and markets generic drugs and pharmaceuticals products. It produces drugs for hypertension, inflammation, depression and pain. The firm distributes its products in the semi-solid form of a cream. The company was founded in 1978 and is headquartered in Chestnut Ridge, NY. | Health Technology |
- Borsa valori
- Insiders
- Joseph A. Barbarite
